What this study is
To evaluate the real-world effectiveness and implementation strategies for mPATH-Lung, investigators propose a pragmatic, randomized controlled trial across an academic Learning Health System. The trial will contrast several approaches to participant outreach and will specifically target engaging fully powered cohorts of racial/ethnic minorities and rural residents.
What's being tested
- Portal Message with Reminder Text Messages
Intervention · OTHER
If the participant has an upcoming scheduled appointment, they will receive a reminder text message 5 days after initial portal message, a final reminder text message a day before their scheduled appointment, and potentially an 'in progress' text message reminder if they start the mPATH-Lung program but do not complete it. If the participant does not have an upcoming scheduled appointment, they will receive a reminder text message 5 days after initial portal message, the final reminder message 8 days after the initial message, and potentially an 'in progress' text message reminder.
- Text Message with Reminder Text Messages
Intervention · OTHER
If the participant has an upcoming scheduled appointment, they will receive a reminder text message 5 days after initial message, a final reminder text message a day before their scheduled appointment, and potentially an 'in progress' text message reminder. If the participant does not have an upcoming scheduled appointment, they will receive a reminder text message 5 days after initial message, the final reminder message 8 days after the initial message, and potentially an 'in progress' text message reminder.
- Portal message only
Intervention · OTHER
Participant will only receive portal message with no reminder text messages.
- Usual Care
Intervention · OTHER
Standard of care
Study details
- Official title
- A Pragmatic Randomized-Controlled Learning Health System Trial
- Sponsor
- Wake Forest University Health Sciences
- Conditions
- Lung Cancer
- Enrolling
- 27,000 people
- Starts
- 2026-03-25
- Est. completion
- 2027-01
- Design
- Single-blind, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 50 Years – 77 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Age 50 - 77 years
- Smoked at least 20 pack years
- Current smoker or quit smoking within the past 15 years
- Be established with a primary care provider within the Atrium Health Wake Forest Baptist health network (defined as having completed at least 1 primary care appointment in the past 6 months or have completed at least 2 primary care appointments within the past 18 months or being scheduled to see a health network primary care provider within the next 30 days).
- Have a patient portal account or cellphone number listed in the electronic health record
- Have a North Carolina address listed in the electronic health record
You can't join if
- Patients flagged as needing a language interpreter in the electronic health record for any language other than Spanish (electronic messages and intervention are deliverable in English or Spanish only)
- Those for whom lung cancer screening would be or may be inappropriate: electronic health record Prior history of lung cancer electronic health record Chest CT within the last 12 months electronic health record Those meeting the HEDIS COL-E measure exclusion criteria based on significant comorbidities and/or frailty.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openAtrium Health Wake Forest Baptist
Winston-Salem, North Carolina, United States
- Study Coordinator, MD · Contact704-355-2000Aliza.randazzo@advocatehealth.org
- Study Coordinator · Contact
- Brent Heideman, Jr., MD · Principal investigator
Recruiting
Study team
Sponsor
Wake Forest University Health Sciences
Study ID IRB00139213
Principal investigator
Brent Heideman, Jr., MD
Wake Forest Baptist Comprehensive Cancer Center
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.